Skip to main content
. Author manuscript; available in PMC: 2019 May 23.
Published in final edited form as: J Innate Immun. 2018 May 23;10(3):228–238. doi: 10.1159/000488914

Figure 4. Role of HO-1 metabolic products.

Figure 4

(A–B) Control and HO-1 deficient Caco2 IECs were treated with biliverdin and bilirubin (50 μM) overnight and then stimulated with IL-1β (1 ng/mL) for 3h. IL-8 was measured by qPCR. Data reflects combined results from at least three independent experiments. (C) Cells were exposed to freshly prepared CO releasing molecule, CORM-2 for 1h or its negative control RuCl3, prior to stimulation with IL-1β (1 ng/mL) for 24h. IL-8 was measured by cytokine immunoassay and normalized to mg total protein. Data are representative of results from two independent experiments *, p < 0.05, ***, p < 0.001 vs untreated control NTC shRNA cells or other comparison shown. #, p < 0.05 vs IL-1β treated NTC shRNA cells.